Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-κB signaling pathway

Immunobiology

Volumn 216, Issue 3, 2011, Pages 367-373

  Bhaskar, Shobha ^a   Shalini, V ^a   Helen, A ^a  

^a UNIVERSITY OF KERALA   (India)

Author keywords

Atherosclerosis; Flavonoids; Inflammation; Ox LDL; Quercetin; Toll like receptors

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; QUERCETIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

ARTICLE; CELL ISOLATION; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

COPPER SULFATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; QUERCETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 79251598329     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.07.011     Document Type: Article

References (34)

1. Axelrod B., Cheesebrough T.M., Laakso S. Lipoxygenase from soyabean. Methods Enzymol. 1981, 71:441-445.
2. Bravo L. Polyphenols: chemistry, dietary sources, metabolism and nutritional significance. Nutr. Rev. 1998, 56:317-333.
3. Carmela S., Rosaria V., Beatrice S., Robertia D.B., Carmela F., Roberta M. Polyphenols, intracellular signaling and inflammation. Ann. Ist Sanita 2007, 43:394-405.
4. Clett E. The roles of Toll-like receptors in atherosclerosis. J. Innate Immun. 2009, 1:340-349.
5. Comalada M., Camuesco D., Sierra S., et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappa pathway. Eur. J. Immunol. 2005, 35:584-592.
6. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105:1158-1160.
7. Erridge C., Burdess A., Jackson A.J., Murray C., Riggio M., Lappin D., Milligan S., Spickett C.M., Webb D.J. Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma. Eur. J. Clin. Invest. 2008, 38:713-720.
8. Flórez S.M., Fernández B.G., Campos S.S., Gallego J.G., Tuñón M.J. Quercetin attenuates nuclear factor-κB activation and nitric oxide production in interleukin-1β - activated rat hepatocytes. J. Nutr. 2005, 135:1359-1365.
9. Gladson M., John J.B. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocytes. J. Clin. Immunol. 2004, 24:542-552.
10. Han C.Y., Park S.Y., Pak Y.K. Role of endocytosis in the transactivation of nuclear-κB by oxidized low-density lipoprotein. Biochem. J. 2000, 350:829-837.
11. Han S.N., Meydani M., Wu D., et al. Effect of long-term dietary antioxidant supplementation on influenza virus infection. J. Gerontol. A Biol. Sci. Med. Sci. 2000, 55:496-503.
12. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
13. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoprotein in human serum. J. Clin. Invest. 1995, 34:1345-1353.
14. Hoebe K., Georgel P., Rutschmann S., et al. CD36 is a sensor of diacylglycerides. Nature 2005, 433:523-527.
15. Hollmann P.C.H., Katan M.B. Bioavailability and health effects of dietary flavonoids in man. Arch. Toxicol. 1998, 20:237-240.
16. Hou D.X., Yanagita T., Uto T., Masuzaki S., Fujii M. Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: structure-activity relationship and molecular mechanisms involved. Biochem. Pharmacol. 2005, 70:417-425.
17. Hougee S., Sanders A., Faber J., et al. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem. Pharmacol. 2005, 69:241-248.
18. Jiang B., Xu S., Hou X., Pimental D.R., Brecher P., Cohen R.A. Temporal control of NF-kappaB activation by ERK differentially regulates interleukin-1beta-induced gene expression. J. Biol. Chem. 2004, 279:1323-1329.
19. Ko C.H., Shen S.C., Lin H.Y., Hou W.C., Lee W.R., Yang L.L., Chen Y.C. Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E2 in anti-promotive process. J. Cell. Physiol. 2002, 193:93-102.
20. Kuhnau J. The flavonoids: a class of semi-essential food components: their role in human nutrition. World Rev. Nutr. Diet. 1976, 24:177-179.
21. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr. Opin. Lipidol. 2003, 14:421-430.
22. Liu J., Li X., Yue Y., Li J., He T., He Y. The inhibitory effect of quercetin on IL-6 production by LPS stimulated neutrophils. Cell. Mol. Immunol. 2005, 2:455-460.
23. Lowry O.H., Roseburgh N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
24. Masakazu S., Ken-ichi H., Tomoya Y., Tomofumi T., Naoto S., Rio S., Tomomi U., Noriaki E., Nobutaka I., Mitsuhiro Y., Seinosuke K. Local overexpression of Toll like receptors at the vessel wall induces atheroscleotic lesion formation synergism of TLR2 and TLR4. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2384-2391.
25. Michelsen K.S., Doherty T.M., Shah P.K., Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J. Immunol. 2004, 173:5901-5907.
26. Michelsen K.S., Wong M.H., Shah P.K., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10679-10684.
27. Mohan R.D., Andrea C.R., Ishwarlal J. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 2009, 202:76-83.
28. Otsui K., Ionue N., Kobayashi S., Shiraki R., Hongo T., Takahashi M., Kawashima S., Yokoyama M. Enhanced expression of TLR4 in smooth nuscle cells in human atherosclerotic coronary arteries-role of inflammatory cytokines. Circ. J. 2005, 69:639.
29. Radhika A., Jacob S.S., Sudhakaran P.R. Influence of oxidatively modified LDL on monocyte-macrophage differentiation. Cell Mol. Biol. 2007, 305:133-143.
30. Radmark O., Samuelsson B. 5-lipoxygenase: regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat. 2007, 83:162-174.
31. Sabroe I., Read R.C., Whyte M.K., Dockrell D.H., Vogel S.N., Dower S.K. Toll-like receptors in health and disease: complex questions remain. J. Immunol. 2003, 171:1630-1635.
32. Shimizu T., Kondo K., Hayaishi O. Role of prostaglandin endoperoxidases in the serum thiobarbituric acid reaction. Arch. Biochem. Biophys. 1984, 206:271-276.
33. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
34. Thao N.K., Ziad A.M., Sarsat V.W., Canteloup S., Latscha B.D. Oxidized low density lipoprotein induces macrophage respiratory burst via its protein moiety: a novel pathway in atherogenesis. Biochem. Biophys. Res. Commun. 1999, 263:804-809.